Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 44 for “"Anti-CD19"”.

  1. Anti-CD19-konjugierte Zytostatika-Liposomen zur gezielten Therapie der pädiatrischen B-Zell-Leukämie

    … vesikuläre Lipid-Nanocarrier, die mit Antikörpern gegen möglichst tumorzellspezifische Oberflächen-Antigene funktionalisiert sind. Dies soll eine gezielte Akkumulation und Freisetzung des verkapselten Wirkstoffs an oder innerhalb der Tumorzellen ermöglichen.<br>Im Rahmen der …

    freiburg-diss Repository record for Anti-CD19-konjugierte Zytostatika-Liposomen zur gezielten Therapie der pädiatrischen B-Zell-Leukämie (opens in a new tab)

  2. EFFECT OF B CELL MODULATION VIA NON-DEPLETING ANTI-CD19 ANTIBODY ON MYOCARDIAL PHYSIOLOGY

    … study, we investigated the impact of targeting CD19 on B cell function and cardiac physiology in C57BL6J mice. In vitro treatment of primary mouse splenic B cells with anti-CD19 monoclonal antibody (mAb) induced internalization of surface CD19 on mouse splenic B cells and led to a reduction in B …

    jhu Repository record for EFFECT OF B CELL MODULATION VIA NON-DEPLETING ANTI-CD19 ANTIBODY ON MYOCARDIAL PHYSIOLOGY (opens in a new tab) Embargoed until 2028-05-01

  3. Chimeric ANTI-CD19 Monoclonal Antibodies for the Treatment of Precursor B Cell Acute Lymphoblastic Leukemia

    … immunotherapies for them are based on anti-CD20 monoclonal antibodies (MAbs). However, CD20 is not expressed on precursor B cell acute lymphoblastic leukemia (pre-B ALL), and CD20 expression is often lost following anti-CD20 immunotherapy. CD19 is a pan B cell membrane antigen that is …

    utswmed Repository record for Chimeric ANTI-CD19 Monoclonal Antibodies for the Treatment of Precursor B Cell Acute Lymphoblastic Leukemia (opens in a new tab)

  4. Improving persistence of anti-CD19 CAR T cells via overexpression of the IL-21 receptor

    Adoptive transfer of anti-CD19 chimeric antigen receptor (CAR) T cells has revolutionized the therapy of relapsed/refractory B-cell precursor ALL. High initial remission rates are nevertheless hampered by a lack of long-term persistence due to T cell exhaustion. Sustained proliferation and …

    lmu-germany Repository record for Improving persistence of anti-CD19 CAR T cells via overexpression of the IL-21 receptor (opens in a new tab)

  5. T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies

    … with a specific view on the immunostimulation of anti- CD19/CD20 × CD3 bispecific antibodies (CD19-BsAb and CD20-BsAb, respectively) in this process. Methods: Our published microarray-based gene dataset was used for gene set enrichment analysis, functional annotation and clustering analysis. A …

    fu-berlin Repository record for T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies (opens in a new tab)

  6. PC3-Feederzell-basierte ex vivo Expansion primärer CAR-NK-Zellen mit anti-CD19-CARs unterschiedlicher Affinität unter Berücksichtigung von Trogozytose

    … Rolle. Insbesondere die Zulassung von chimären Antigenrezeptor (CAR)-T-Zelltherapien gegen B-Zell-spezifische Marker wie D19 hat das therapeutische Spektrum erheblich erweitert. Dennoch werden T-Zell-basierte Therapien mit erheblichen Nebenwirkungen assoziiert. Vor diesem Hintergrund rücken …

    qucosa-diss

  7. Delineating the apoptotic mechanisms of an anti-CD19 immunotoxin used in combination with the anti-CD20 antibody rituximab against human B-lymphoma cells

    <p>The aim was to determine the effect of rituximab and BU12-saporin individually and in combination on B lymphoma cell lines and determine the contribution of complement mediated mechanisms. In an <i>in vitro</i> protein synthesis inhibition assay, using Burkitt’s lymphoma cells, the presence of …

    soton Download PDF for Delineating the apoptotic mechanisms of an anti-CD19 immunotoxin used in combination with the anti-CD20 antibody rituximab against human B-lymphoma cells (opens in a new tab)

  8. Engineering a CD19-Based Bispecific Molecule for CAR T Cell Therapy

    … T cell therapy, but more specifically, chimeric antigen receptor (CAR) expressing T cell transfer, has had notable clinical success particularly against hematological malignancies. Chimeric antigen receptors are synthetic immunoreceptors which can redirect T cells towards varying tumor associated …

    umn Repository record for Engineering a CD19-Based Bispecific Molecule for CAR T Cell Therapy (opens in a new tab)

  9. Αποτελεσματικότητα και ασφάλεια των χιμαιρικών αντιγονικών υποδοχέων Τ-κυττάρων σε ασθενείς με υποτροπιάζουσα/ανθεκτική οξεία λεμφοβλαστική λευχαιμία (ΟΛΛ): μία συστηματική ανασκόπηση

    … τυχαιοποιημένων κλινικών μελετών (24 μελέτες με anti-CD19, 2 με anti-CD22, 5 με anti-CD19/CD22 CAR-T κύτταρα) που αφορούν ασθενείς με υποτροπιάζουσα/ανθεκτική Β-ΟΛΛ. Όλες οι κλινικές μελέτες είναι φάσεως 1 ή 2, ανοικτού τύπου, ενώ καμία δεν διέθετε συγκριτική ομάδα ελέγχου. Η κυτταρική θεραπεία …

    athens Repository record for Αποτελεσματικότητα και ασφάλεια των χιμαιρικών αντιγονικών υποδοχέων Τ-κυττάρων σε ασθενείς με υποτροπιάζουσα/ανθεκτική οξεία λεμφοβλαστική λευχαιμία (ΟΛΛ): μία συστηματική ανασκόπηση (opens in a new tab)

  10. Establishing a CRISPR/CAS9-mediated double KI of pro-inflammatory IL-18 into HAVCR2 and 19BB3z into TRAC locus to generate persistent and safe CAR-T-cells

    … but achieving long-term success with chimeric antigen receptor CAR-T-cells remains a challenge. Anti-CD19 CAR-T-cells have recently been approved by the FDA and EMA for treating relapsed or refractory acute lymphoblastic leukemia (ALL). While initial response rates are high, preventing relapse …

    lmu-germany Repository record for Establishing a CRISPR/CAS9-mediated double KI of pro-inflammatory IL-18 into HAVCR2 and 19BB3z into TRAC locus to generate persistent and safe CAR-T-cells (opens in a new tab)

  11. Exploring Novel B-cell Specific Immunomodulatory Adjuvants and Future Implications for HIV Vaccines

    Eliciting broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus-1 (HIV-1). HIV-1 infects CD4 T cells through its envelope glycoprotein trimer (Env), which is the only virally encoded protein on the viral surface and thus serves as a key target for vaccine development. By …

    toronto-retro Repository record for Exploring Novel B-cell Specific Immunomodulatory Adjuvants and Future Implications for HIV Vaccines (opens in a new tab)

  12. From Bench To Bedside And Back Again: Car T Cell Signaling And Survival

    Chimeric Antigen Receptor (CAR) T cell therapies for hematologic malignancies have been astonishingly successful in driving cancer remissions. However, early loss of CAR T cells and return of normal B cells is a predictor of relapse in pediatric acute lymphoblastic leukemia; the duration of …

    penn Repository record for From Bench To Bedside And Back Again: Car T Cell Signaling And Survival (opens in a new tab)

  13. Generation and characterization of CD19 CAR T cells with PD-1_CD28 fusion receptor

    … strategy for B-ALL, adoptive T-cell transfer of CD19 targeting T cells with chimeric antigen receptor (CAR) has emerged. Clinical studies show remission rates of heavily pretreated patients of up to 90% upon CAR T-cell infusion. Despite temporary remission, around 50% of patients treated with a …

    lmu-germany Repository record for Generation and characterization of CD19 CAR T cells with PD-1_CD28 fusion receptor (opens in a new tab)

  14. CD28 CO-STIMULATION AND CANCER IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR-MODIFIED NATURAL KILLER CELLS

    Adaptive immunotherapy using chimeric antigen receptor (CAR) modified immune cells has shown promising clinical benefits for the treatment of cancer. Among different effector immune cells tested for CAR immunotherapy, natural killer (NK) cells are attractive since they, as opposed to T cells, …

    nus Repository record for CD28 CO-STIMULATION AND CANCER IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR-MODIFIED NATURAL KILLER CELLS (opens in a new tab) Download file for CD28 CO-STIMULATION AND CANCER IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR-MODIFIED NATURAL KILLER CELLS (opens in a new tab)

  15. Engineered plasma cells: a novel platform for long-term delivery of biologics to treat leukemia and other diseases

    … of non-immunoglobulin G (IgG)-like bispecific antibodies by human plasma cells to treat leukemias in vivo; b) a humanized mouse model to assess engraftment function and pharmacokinetics of adoptively transferred autologous ePC; and c) a novel B cell signaling BCR/Ab-screening method to evaluate …

    washington Repository record for Engineered plasma cells: a novel platform for long-term delivery of biologics to treat leukemia and other diseases (opens in a new tab)

  16. Cytoskeletal regulation of B cell antigen receptor signaling

    Signaling through the B cell antigen receptor (BCR) is essential for several processes of B cell biology, such as proliferation, differentiation and homeostasis. Accordingly, the signaling events emanating from the BCR have to be tightly regulated in order to ensure an effective immune response and …

    freiburg-diss Repository record for Cytoskeletal regulation of B cell antigen receptor signaling (opens in a new tab)

  17. Generating CAR γδ T Cells for Effective Targeting of B Lymphomas

    Chimeric antigen receptor (CAR) T-cell therapy has attracted growing interest in the treatment of various malignancies and represents the most advanced technology to date. This approach involves the use of genetically engineered immune cells expressing a surface receptor, called CAR, that …

    ottawa-retro Repository record for Generating CAR γδ T Cells for Effective Targeting of B Lymphomas (opens in a new tab)

  18. Investigation of lentiviral vectors incorporating HIV-1 envelopes for their application in human in vivo gene therapy

    … To demonstrate functional transgene activity, an anti-CD19 chimeric antigen receptor (CAR) was delivered to CD4+ T cells, resulting in the generation of CAR T cells. These CD4+ CAR T cells exhibited specific cytotoxicity against CD19-expressing cancer cell lines. Finally, HIV-1 enveloped vectors …

    kings Repository record for Investigation of lentiviral vectors incorporating HIV-1 envelopes for their application in human in vivo gene therapy (opens in a new tab) Download PDF for Investigation of lentiviral vectors incorporating HIV-1 envelopes for their application in human in vivo gene therapy (opens in a new tab)

  19. Leveraging Systems Immunology To Understand The Molecular Underpinnings Of Chimeric Antigen Receptor T-Cell Therapy

    Chimeric Antigen Receptor (CAR) T-cell therapy is a promising strategy for the treatment of human cancers, and in the last decade has progressed from breakthrough early trials to first in class FDA approvals for B-cell leukemias and lymphomas. Concurrent with the promise and challenges in cancer …

    penn Repository record for Leveraging Systems Immunology To Understand The Molecular Underpinnings Of Chimeric Antigen Receptor T-Cell Therapy (opens in a new tab)

Page 1 of 3